Phase 3 will include 12 weeks of patients follow-up, including clinical visits at weeks 1, 2, 4, 8 and 12 post treatment. During this phase, subjective and objective measures of alcohol use (self-report and analysis of urine samples for levels of ethyl glucuronide (EtG) and ethyl sulfate (EtS) [2], respectively) will be collected. Following completion of the main part by the individual, an "open label" treatment using the same parameters of the experiment will be offer (regardless of treatment group).